Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
LONDON, May 13, 2014 /PRNewswire/ --
OBN - the membership organisation supporting the UK's emerging life sciences companies - today hosts the launch at BioTrinity 2014 of the European Policy Dialogue for Growth (EPDG) initiative to address the shortage of financing for life sciences start-ups in Europe.
"Although European life sciences venture capital financing is growing year-on-year, there is still a shortfall, particularly for emerging companies - OBN's core membership - to support their first stages of development," comments Jon Rees, CEO of OBN.
"Much of the work OBN does is around access to finance and therefore it is appropriate we host, in association with LOGOS Public Affairs, the EPDG launch during OBN's flagship BioTrinity Biopartnering and Investor Conference. We have been able to bring in a focus group of senior representatives from the international investor community, BioTrinity conference attendees, to take part in the opening debate. Going forward, we will draw experts from this group to form the OBN Investment Special Interest Group, interfacing with EPDG and representing the interests of emerging companies to government in similar future initiatives and forums."
EPDG Chair Dr William Brooks comments, "Shortage of finance for emerging companies is not a new problem. Without revising policy tools and adjusting its current financing measures, the European Union will fail to translate R&D innovation into its full potential, negatively impacting both its economic future and its citizens' health. We hope that this series of planned high-level debates, engaging industry stakeholders and funders with EU officials, will uncover novel ways to shape the role of the EU's financing mechanisms, help early stage companies get their products to market and become self-sustaining."
The EPDG initiative is managed by LOGOS Public Affairs, Brussels. Further details are available to download here http://www.logos-eu.com/documents/EPDG Briefing Note.pdf.
OBN is the membership organisation supporting and bringing together the UK's emerging life sciences companies, corporate partners and investors. Our Membership of over 300 companies, spread across the Golden Triangle (formed by the cities of Oxford, Cambridge and London) and beyond to Nottingham, Manchester and Scotland, benefits from tailored networking and partnering events, group purchasing, advice, consultancy and advocacy.
OBN founded and produces BioTrinity, Europe's Leading Biopartnering and Investment Conference for emerging companies. Attracting around 1,000 senior delegates from Europe, Asia and North America, BioTrinity generates more R&D company-to-investor interactions than any similar European event.
About LOGOS Public Affairs
LOGOS is a Public Affairs, Association Management and Stakeholder dialogue company, part of the MCI Group family. The integration of LOGOS into MCI Group creates a unique mix of expertise to support European and International organisations in Brussels and in Europe with their Public Affairs, Association, Communications and Event Management needs.
LOGOS Public Affairs is a member of the European Public Affairs Consultancies Association. We have signed the EPACA Code of Conduct.
Find out more about our team and services at: http://www.logos-eu.com.
Jon Rees, CEO
Tel: +44(0)845-5049-722 or +44(0)7795-233883
For media interview requests contact:
Val Tate, Director of Communications
Logos Public Affairs
Kathrin Ludwig, EPDG Project Manager
©2012 PR Newswire. All Rights Reserved.